Zelira Therapeutics (AU:ZLD) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zelira Therapeutics is gearing up to present its latest business advancements at the Automic Invest 2024 conference, highlighting its successful proprietary cannabinoid medications like HOPE® and ZENIVOL®. With a robust pipeline and strategic partnerships, Zelira is expanding its market presence in the US, Australia, and Germany, aiming for significant growth in the global cannabinoid-based medicine sector.
For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.